Fubotv earnings beat by $0.10, revenue topped estimates
NAARDEN/MIAMI - NewAmsterdam Pharma (NASDAQ:NAMS) announced Wednesday that its experimental drug obicetrapib significantly reduced plasma p-tau217, a key biomarker of Alzheimer’s disease pathology, according to data from a prespecified analysis of its BROADWAY clinical trial. The company, currently valued at $2.6 billion, has seen its stock surge over 40% in the past year, reflecting growing investor confidence in its drug development pipeline. According to InvestingPro data, the stock is currently trading near its Fair Value, with analysts setting price targets up to $52.26.
The analysis showed that daily treatment with obicetrapib 10 mg for 12 months led to statistically significant reductions in p-tau217 levels in both the full analysis set (p=0.0019) and in ApoE4 carriers (p=0.0215), a group at higher risk for developing Alzheimer’s disease. InvestingPro analysis reveals the company maintains a strong financial position with a current ratio of nearly 20x, indicating robust liquidity to support its ongoing clinical programs.
The effect was most pronounced in carriers of two E4 proteins, considered the highest risk category for Alzheimer’s disease, where obicetrapib reduced p-tau217 levels by 20.5% compared to placebo (p=0.010).
The data was presented at the 2025 Alzheimer’s Association International Conference in Toronto.
The BROADWAY trial primarily evaluated obicetrapib, a CETP inhibitor, for LDL cholesterol reduction in patients with established atherosclerotic cardiovascular disease and/or heterozygous familial hypercholesterolemia. The Alzheimer’s biomarker analysis included 1,515 patients whose ApoE status was determined, including 367 ApoE4 carriers.
Favorable trends were also observed across additional biomarkers, including neurofilament light chain, glial fibrillary acidic protein, p-tau181, and the Aβ42/40 ratio.
"These results advance our understanding of how upstream lipid modulation may influence Alzheimer’s disease risk, especially in individuals carrying the ApoE4 protein," said Philip Scheltens, Professor Emeritus at Amsterdam UMC, in the company’s press release.
No separate safety analysis was conducted for the Alzheimer’s study population, but in the overall BROADWAY trial, obicetrapib was reported to be well-tolerated with safety results comparable to placebo.
The company stated it plans to discuss these results with regulatory authorities to determine potential next steps.
In other recent news, NewAmsterdam Pharma has been the focus of several analyst ratings and corporate updates. Goldman Sachs initiated coverage on NewAmsterdam Pharma with a Neutral rating, setting a price target of $27.00, due to the extended timeline for the Phase 3 PREVAIL cardiovascular outcomes trial results for obicetrapib, expected in late 2026. Meanwhile, Citi started coverage with a buy rating and a $42.00 price target, highlighting the significant market potential for obicetrapib, a cholesterol-lowering drug. Cantor Fitzgerald maintained its Overweight rating and $42.00 price target, emphasizing the company’s competitive positioning and the ongoing PREVAIL outcomes study. Stifel reiterated a buy rating with a $44.00 price target, praising the strong data presented at the company’s R&D Day, which reinforced the potential benefits of obicetrapib beyond LDL-C reduction. Additionally, NewAmsterdam Pharma announced an updated employment agreement with Dr. John Kastelein, the chief scientific officer, which includes provisions for termination without cause. These developments reflect the company’s strategic efforts and the anticipation surrounding its lead candidate, obicetrapib.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.